Treatment of older patients with acute myeloid leukemia--new agents

Seminars in Hematology
Alan K Burnett, Unmesh Mohite

Abstract

The experience of most collaborative study groups is that the outcome for older patients has, unlike in younger patients, failed to improve over the last two decades. In addition there are a substantial number of older patients who do not enter collaborative group trials because they are not considered suitable for an intensive chemotherapy approach. During this era many combinations of chemotherapeutic agents at different dose levels have been tried. It is clear that novel agents and new approaches must be used to improve the situation, and should include options for patients who are not fit for intensive treatment. Fortunately, the increased understanding of the molecular basis and heterogeneity of the disease has fostered the development of novel agents. Chemo-resistance is a key characteristic of acute myeloid leukaemia (AML) in older patients and a number of randomized trials have now been completed to assess this approach. New possibilities of selectively killing leukemic cells and/or modifying toxicity are in prospect with the development of antibody directed chemotherapy in the form of gemtuzumab ozogamicin (Mylotarg; Wyeth, Philadelphia, PA). New drugs such as clofarabine or cloretazine are being evaluated. Molecular m...Continue Reading

References

Jan 24, 1992·Journal of Medicinal Chemistry·J A MontgomeryJ A Secrist
Jan 1, 1986·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·R P Warrell, E Berman
Dec 1, 1986·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·B D ChesonM A Friedman
Oct 1, 1984·British Journal of Haematology·G TricotR L Verwilghen
Dec 29, 1983·The New England Journal of Medicine·J S WischD W Kufe
Sep 29, 1999·Advances in Experimental Medicine and Biology·R PirkerM Filipits
Jun 16, 2001·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·R A PeckM J Hawkins
Aug 15, 2002·Blood·D Gary Gilliland, James D Griffin
Nov 26, 2002·Seminars in Hematology·Razelle KurzrockHagop Kantarjian
Mar 15, 2003·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Hagop M KantarjianMichael Keating
Mar 29, 2003·Blood·Eric SolaryUNKNOWN Groupe Ouest Est Leucémies Aiguës Myéloblastiques
Sep 13, 2003·Leukemia·M Levis, D Small
Feb 5, 2004·Molecular Cell·James GriffithKumkum Saxena
May 8, 2004·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Francis GilesHagop Kantarjian
Jan 6, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Dimitri A BreemsBob Löwenberg

❮ Previous
Next ❯

Citations

May 9, 2012·European Journal of Clinical Pharmacology·Savitha VaratharajanPoonkuzhali Balasubramanian
May 27, 2009·Current Opinion in Hematology·Raphael Itzykson, Pierre Fenaux
Feb 24, 2010·Current Opinion in Hematology·Arturo Loaiza-BonillaHetty E Carraway
Nov 11, 2010·Molecular Cancer Therapeutics·Lulu FarhanaJoseph A Fontana
Jun 19, 2007·Drugs & Aging·Arumugam ManoharanUNKNOWN Australasian Leukaemia and Lymphoma Group
May 23, 2014·Clinical Interventions in Aging·Ming Y Lim, Katarzyna Jamieson
Dec 7, 2010·Best Practice & Research. Clinical Haematology·Harry P Erba
Jul 7, 2009·Biochemical Pharmacology·Anna ZhenchukFreidoun Albertioni
Apr 7, 2009·Cancer Letters·Eric OlmMikael Björnstedt
Mar 18, 2009·British Journal of Haematology·Alan K BurnettUNKNOWN United Kingdom National Cancer Research Institute Haematological Oncology Study Group
Feb 15, 2011·British Journal of Haematology·Daniel A PollyeaBruno C Medeiros
Nov 13, 2007·Critical Reviews in Oncology/hematology·Felicetto FerraraFranco Leoni
May 5, 2010·Oncology Nursing Forum·Barbara B Rogers
Feb 1, 2011·Clinical Journal of Oncology Nursing·Amanda DresselAnn M McGreal
Jun 19, 2016·The Kaohsiung Journal of Medical Sciences·Jia-Jie LuanWu-San Wang
Dec 23, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Gary J SchillerFrancis J Giles
Apr 14, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Alan K BurnettRobert K Hills
Feb 25, 2009·Expert Opinion on Pharmacotherapy·Xavier Thomas
Aug 5, 2014·American Journal of Hematology·Melhem SolhCelalettin Ustun
Nov 25, 2006·Hematology·Charles A Schiffer
Mar 7, 2007·Expert Review of Anticancer Therapy·Gail J Roboz

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antibody-Dependent Cell Cytotoxicity

Antibody-dependent cellular toxicity refers to the lysis of a target cell by a non-sensitized effector cell of the immune system as a result of antibodies binding to the target cell membrane and engaging the Fc receptors on the immune effector cells. Find the latest research on antibody-dependent cellular toxicity here.

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.

Related Papers

Best Practice & Research. Clinical Haematology
Martin S Tallman
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
Elihu Estey
© 2022 Meta ULC. All rights reserved